EVOLVE
2012
Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events
In 3,883 haemodialysis patients with secondary hyperparathyroidism, cinacalcet did not significantly reduce death or cardiovascular events compared with placebo.
Result
Efficacy: Composite of death or first non-fatal cardiovascular eventHR 0.93 (95% CI 0.85-1.02) · P = 0.11
Below 1 favours cinacalcet, above 1 favours placebo.
- Absolute difference
- 1.0 points
The absolute difference is derived from the event rates.
Also reported: Age-adjusted HR 0.88.
- Subtopic
- Mineral & bone disorder
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Chertow GM, et al. N Engl J Med. 2012;367(26):2482-2494.doi 10.1056/NEJMoa1205624
Discussion & critique
No universal CV benefit; high dropout and crossover; cinacalcet is now used selectively in refractory disease.